J&J's Palmaz-Schatz stent
This article was originally published in The Gray Sheet
Executive Summary
Six-month follow-up of a randomized trial comparing the Johnson & Johnson Heparin coated stent with balloon angioplasty in patients with acute myocardial infarction shows a 12.4% risk of death, repeat MI, disabling cerebrovascular accident and ischemia-driven target vessel revascularization in the stent arm compared to 20.1% in the angioplasty arm (p<0.01), the study's primary endpoint. Results from the 62-center, 900 patient trial were presented at an AHA press conference Nov. 9 by Cindy Grines, MD, William Beaumont Hospital, Royal Oak, Michigan. The results also show reduced restenosis in the stent arm (20.3% vs. 32.5%; p<0.001) and reduced angina (11.1% vs. 16.9%; p<0.02). Six-month reocclusion rates were also favorable compared to PTCA (10-13%) and thromobolytic therapy (30%), Grines noted. "In the era of stenting it looks like we've reduced that down to 4%, that's a major improvement and could potentially reduce rates of reinfarction" and improve LV function, Grines said
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.